Neuromyelitis optica spectrum disorder (NMOSD) is a rare autoimmune condition in which the immune system attacks the optic nerves, spinal cord, and certain parts of the brain. It affects roughly 7 per 100,000 people in the United States, and it can cause severe vision loss, paralysis, and other neurological damage that often doesn’t fully recover between attacks. NMOSD was once considered a form of multiple sclerosis, but it has a distinct biological cause and requires different treatment.
What Happens in the Body
In most cases of NMOSD, the immune system produces an antibody called AQP4-IgG that targets a protein found on certain brain and spinal cord cells called astrocytes. Astrocytes are support cells that help maintain the barrier between the bloodstream and the brain, regulate fluid balance, and keep nerve cells healthy. The AQP4 protein sits on the surface of astrocyte “end-feet,” the parts of these cells that wrap around blood vessels in the central nervous system.
When AQP4-IgG antibodies bind to this protein, they trigger a chain of immune reactions that destroys the astrocytes. The immune system’s complement system, a set of proteins that normally fights infections, is activated and forms what’s called a membrane attack complex that punches holes in astrocyte membranes. This destruction causes intense inflammation, damages the protective myelin coating on nearby nerve fibers, and leads to the neurological symptoms of NMOSD. Because AQP4 is concentrated in the optic nerves, spinal cord, and a specific area of the brainstem, those are the regions most often affected.
Core Symptoms
NMOSD typically presents with three hallmark patterns, though not every person experiences all of them.
Optic neuritis is the most recognizable symptom. It causes sudden, painful vision loss, usually in one eye at a time, though both eyes can be affected simultaneously or weeks apart. Over half of patients report decreased visual acuity, and nearly 58% eventually lose the ability to drive due to visual disability.
Transverse myelitis involves inflammation of the spinal cord, causing weakness or paralysis in the legs (and sometimes arms), numbness, and loss of bladder or bowel control. About 44% of patients report muscle weakness, and bladder control problems affect roughly a quarter of those who have had only a single attack. These numbers climb with each relapse.
Area postrema syndrome is a lesser-known but important clue. The area postrema is a small region at the base of the brainstem that controls nausea and vomiting. When NMOSD attacks this area, it causes bouts of uncontrollable hiccups, nausea, and vomiting that can last weeks. In one case series, vomiting lasted a median of four weeks. These episodes are often initially misdiagnosed as a gastrointestinal problem. Persistent, unexplained hiccups or vomiting, especially combined with any vision changes or limb weakness, should raise suspicion for NMOSD.
Who Gets NMOSD
NMOSD disproportionately affects women, with a female-to-male ratio of about 3.5 to 1. Among women in the U.S., prevalence reaches 9.48 per 100,000, compared to 3.52 per 100,000 in men. Race plays a significant role as well. Black Americans have the highest prevalence at nearly 13 per 100,000, followed by Asian Americans at 9.4 per 100,000 and White Americans at 5.6 per 100,000. Black women are hit hardest, with a prevalence of 19.16 per 100,000, roughly 2.7 times higher than White women.
Interestingly, these racial disparities are more pronounced in the U.S. than in the populations’ countries of origin. African populations have far lower rates (0.004 to 0.2 per 100,000), and Asian country-specific rates range from about 1.9 to 4.1 per 100,000, well below the 9.4 seen in Asian Americans. Researchers suspect genetic admixture and environmental factors in the U.S. may contribute to this pattern.
How NMOSD Differs From Multiple Sclerosis
The distinction between NMOSD and MS matters because treatments that work for MS can actually worsen NMOSD. The two conditions look different on MRI in ways that help doctors tell them apart.
Spinal cord lesions are the clearest differentiator. In NMOSD, lesions tend to be long, stretching continuously across three or more vertebral segments and sitting in the center of the spinal cord. MS lesions are typically shorter (rarely more than one vertebral segment), patchy rather than continuous, and positioned near the outer edges of the cord. These differences are reliable enough that trained radiologists can often distinguish the two conditions from spinal MRI alone, particularly during an acute attack.
The antibody test also helps. About 70 to 80% of people with NMOSD test positive for AQP4-IgG antibodies, which are not found in MS. A related condition called MOGAD (myelin oligodendrocyte glycoprotein antibody-associated disease) can mimic both NMOSD and MS but involves a different antibody. Sorting out which condition a person has is one of the first priorities after symptoms appear.
Diagnosis
The current diagnostic framework, established by the 2015 International Panel for NMO Diagnosis and reaffirmed by consensus guidelines through 2025, divides NMOSD into two categories based on antibody status.
For people who test positive for AQP4-IgG, diagnosis requires at least one core clinical feature: optic neuritis, spinal cord inflammation, area postrema syndrome, or involvement of other brainstem or brain regions. The bar is lower because the antibody itself is highly specific to the disease.
For people who test negative for AQP4-IgG (or whose test results are unavailable), the criteria become stricter. Doctors need more specific clinical features combined with particular MRI findings to make the diagnosis with confidence. This ensures that AQP4-negative patients aren’t misdiagnosed when they may actually have MS or MOGAD.
The gold standard for antibody testing is a live cell-based assay, which uses living cells engineered to express AQP4 on their surface. This method is more sensitive than older techniques, though access to live cell-based assays remains limited in some parts of the world.
What Relapses Mean for Long-Term Health
NMOSD is a relapsing disease for most people, and each attack carries the risk of permanent damage. Unlike MS, where relapses often partially resolve, NMOSD attacks tend to leave more lasting disability. In a large study of NMOSD patients, those who experienced three or more relapses had a median disability score of 5.5 on a standard 10-point scale, meaning they needed assistance to walk. Patients with only a single attack scored a median of 2.5, indicating minimal disability.
Bladder control problems affected about 26% of patients after a single attack but jumped to over 40% after one relapse. Bowel control issues followed a similar trajectory. Nearly half of all patients reported being unable to drive due to motor or visual problems. The cumulative nature of this damage is why preventing relapses is the central goal of NMOSD treatment.
How Attacks Are Treated
When an NMOSD attack strikes, the standard first step is high-dose intravenous corticosteroids, typically given daily for five days. This aims to rapidly reduce inflammation and limit nerve damage. However, steroids alone provide only moderate recovery for many patients.
If symptoms don’t improve sufficiently with steroids, or if the attack is severe from the start, plasma exchange (sometimes called PLEX) is added. This procedure filters the blood to remove the harmful antibodies circulating in it. Patients typically undergo five to seven sessions over the following week. Studies show that combining plasma exchange with steroids leads to better outcomes than steroids alone, particularly for patients already on preventive medications.
Long-Term Prevention
Because each relapse can cause irreversible damage, most people with AQP4-positive NMOSD are started on long-term preventive therapy. Four targeted medications now have FDA approval specifically for this condition, all designed to interrupt different steps in the immune attack.
Two of these drugs block the complement system, the part of the immune response that directly destroys astrocytes. They are given as intravenous infusions, one every two weeks and the other at longer intervals. A third medication depletes a type of immune cell called B cells, including the specific cells thought to produce the harmful AQP4 antibodies. It’s given intravenously every six months after initial loading doses. The fourth blocks a signaling molecule called IL-6 that promotes inflammation, reduces the production of autoantibodies, and helps maintain the blood-brain barrier. It’s given as an injection under the skin every four weeks.
For patients who don’t have access to these newer biologics, older immunosuppressant medications remain an alternative. Current guidelines recommend choosing a treatment based on availability, patient-specific factors, and whether the person is planning pregnancy. For women considering pregnancy, guidelines suggest planning after at least 12 months of disease stability and resuming treatment promptly after delivery, since the postpartum period carries an elevated relapse risk.